Treatment of diseases using enantiomerically pure hydroxylated xanthine compounds
AssigneeCell Therapeutics, Inc.
InventorsJames A. Bianco, Paul Woodson, David Porubek, Jack Singer
Life of this patent
Estimating the term…
Abstract
There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
Claims5
A method for treating a disease mediated by abnormal IL-1 signaling activity, comprising administering an effective amount of a compound wherein the compound has a formula:
- ##STR7## wherein:
- R.sub.1 is a substantially pure resolved R enantiomer .omega.-1, secondary alcohol-substituted alkyl (C.sub.5-8) group;
- and
- R.sub.2 and R.sub.3 are independently hydrogen atom or an alkyl (C.sub.1-12) or alkoxyl (C.sub.1-12), or a pharmaceutical composition thereof.
A method for treating psoriasis, asthma, osteoporosis, alcoholic hepatitis, or premature labor secondary to uterine infection, comprising administering an effective amount of a compound to an individual in need of such treatment, wherein the compound has a formula:
- ##STR8## wherein:
- R.sub.1 is a substantially pure resolved R enantiomer .omega.-1, secondary alcohol-substituted alkyl (C.sub.5-8) group;
- and
- R.sub.2 and R.sub.3 are independently hydrogen atom or an alkyl (C.sub.1-12) or alkoxyl (C.sub.1-12).
Dependencies are inferred from the claim text.